Stoke Therapeutics Q2 net loss $61.6M; Phase 3 EMPEROR enrollment complete at 162 patients

Stoke Therapeutics, Inc.

Net loss of $61.6M ($0.93 per share) vs $23.5M loss in Q2 2025; revenue fell to $9.3M from $13.8M.
Cash, equivalents and marketable securities $420M (incl. $65.7M post-quarter ATM sale); funds operations to potential 2028 launch.
Phase 3 EMPEROR study of zorevunersen enrolled 162 patients; data readout expected Q3 2027.
Pre-NDA meeting with FDA scheduled H2 2026; rolling NDA submission to begin Q1 2027.
Phase 1 OSPREY study of STK-002 for ADOA: sentinel cohort dosed, initial data anticipated H1 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.